Indeed, preclinical models have demonstrated that 89Zr-DFO-MSTP2109A, derived from a fully humanized monoclonal STEAP1 antibody, cannot only detect PCa with high STEAP1 expression but also reflect treatment effectiveness by measuring the expression in these models [20]. Here, STEAP1 is linked to posterior cortical atrophy.